Research Biosimilar Antibodies | Biosimilar Reagents

Access 2,500+ research biosimilar antibodies produced using the same variable-region sequences as approved therapeutic antibodies. Covering targets across oncology (HER2, EGFR, PD-1/PD-L1, CD20), autoimmune disease (TNF-α, IL-6R, IL-17A), and ophthalmology (VEGF). Designed for mechanism-of-action studies, ADA/PK assay development, and preclinical pharmacology at research-grade pricing. All products are designated Research Use Only (RUO) — not intended for diagnostic or therapeutic procedures. RUO

Why Researchers Choose abinScience

Same Variable Region as Originator Produced with published CDR sequences matching the approved therapeutic — enabling direct comparison studies and reference standard development.

ADA & PK Assay Development Ideal as positive controls, calibration standards, and coating antigens in anti-drug antibody (ADA) screening and pharmacokinetic (PK) drug monitoring assays.

Broad Therapeutic Coverage References to trastuzumab, adalimumab, pembrolizumab, nivolumab, rituximab, bevacizumab, atezolizumab, durvalumab, and 100+ other approved or pipeline therapeutics.

Research-Grade Pricing Access therapeutic antibody sequences at a fraction of clinical-grade cost — no licensing fees, no minimum orders, ready for immediate research use.